UBS reiterates its 'buy' recommendation on Scor despite a price target lowered from 35.1 to 33.7 euros, representing an estimated upside potential of 12% for the stock, following the French reinsurer's release of its first-quarter results on Friday.

The broker remains positive 'despite emerging new mortality concerns in the US, with the build-up of a reserve cushion in the P&C business being overlooked'. It also points to a P/E ratio of 6.3x for Scor, compared with 9-12x for its peers.

Copyright (c) 2024 CercleFinance.com. All rights reserved.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.